WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 407208
Description: AZ0108 is an orally bioavailable, potent PARP1,2,6 inhibitor that potently inhibits centrosome clustering and is suitable for in vivo efficacy and tolerability studies. AZ0108 has been utilized as in vitro tools and in vivo probes to investigate the biological consequences of inhibiting centrosome clustering through PARP enzymes. AZ0108 is more selective in its enzyme inhibition profile and effects on cellular pathways and phenotypes. Specifically, AZ0108 inhibits PARPs 1, 2, and 6 with approximately 100-fold selectivity against PARP3 and TNKS1. Consistent with this lack of potencytowards tankyrase, AZ0108 is not active in a DLD-1 Wnt luciferase reporter assay.
MedKoo Cat#: 407208
Chemical Formula: C24H20F4N6O2
Exact Mass: 500.1584
Molecular Weight: 500.4576
Elemental Analysis: C, 57.60; H, 4.03; F, 15.18; N, 16.79; O, 6.39
AZ0108 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Synonym: AZ0108; AZ-0108; AZ 0108.
IUPAC/Chemical Name: (S)-4-((3-(3-(1,1-difluoroethyl)-6-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine-7-carbonyl)phenyl)difluoromethyl)phthalazin-1(2H)-one
InChi Key: NWGMIELHSCQGOG-ZDUSSCGKSA-N
InChi Code: InChI=1S/C24H20F4N6O2/c1-13-11-34-18(29-32-22(34)23(2,25)26)12-33(13)21(36)14-6-5-7-15(10-14)24(27,28)19-16-8-3-4-9-17(16)20(35)31-30-19/h3-10,13H,11-12H2,1-2H3,(H,31,35)/t13-/m0/s1
SMILES Code: FC(F)(C1=CC=CC(C(N2[C@H](CN3C(C2)=NN=C3C(F)(C)F)C)=O)=C1)C4=NNC(C5=CC=CC=C54)=O
The following data is based on the product molecular weight 500.4576 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Johannes JW, Almeida L, Daly K, Ferguson AD, Grosskurth SE, Guan H, Howard T,
Ioannidis S, Kazmirski S, Lamb ML, Larsen NA, Lyne PD, Mikule K, Ogoe C, Peng B,
Petteruti P, Read JA, Su N, Sylvester M, Throner S, Wang W, Wang X, Wu J, Ye Q,
Yu Y, Zheng X, Scott DA. Discovery of AZ0108, an orally bioavailable
phthalazinone PARP inhibitor that blocks centrosome clustering. Bioorg Med Chem
Lett. 2015 Dec 15;25(24):5743-7. doi: 10.1016/j.bmcl.2015.10.079. Epub 2015 Oct
27. PubMed PMID: 26546219.